Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign informed consent.~* Male or female 6-12 years old.~* Negative pregnancy test.~* Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD.~* No co-morbid illness that could affect safety, tolerability or interfere with participation.~* Blood pressure (BP) within the 95th percentile for age, gender, and height.~* Willing and able to comply with all the requirements defined in protocol.~Exclusion Criteria:~* Current controlled (requiring a restricted medication) or uncontrolled co-morbid psychiatric diagnosis (except Oppositional Defiant Disorder \[ODD\]).~* At risk for suicidal or violent behavior towards self or others.~* History of a suicide attempt.~* History of a structural cardiac abnormality or other serious cardiac problems.~* Non-responder to psychostimulant treatment.~* Is overweight.~* Seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.~* Has Conduct Disorder.~* Known history of alcohol or other substance abuse within the last 6 months.~* Any abnormal thyroid function.~* A concurrent chronic or acute illness, disability, or other condition that might confound results of safety assessments.~* Has had treatment with any known liver altering agents within 30 days prior to Screening.~* Taking any excluded medication.~* Previous use of DAYTRANA.~* Taking other medications that have Central Nervous System (CNS) effects.~* Female subject is pregnant or lactating.~* Has any skin disease, or history of any chronic skin disease, skin cancer, skin manifestations of allergic disease, or other dermatologic conditions.~* Has sensitive-skin syndrome or has sensitivities to the ingredients in soaps, lotions, cosmetics or adhesives.~* Has clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites.~* A documented allergy, hypersensitivity or intolerance of methylphenidate (MPH) or any components found in DAYTRANA.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: EXPERIMENTAL): To characterize the dermal reactions seen with the use of DAYTRANA

Based on this trial design, predict the completion outcome and termination type (if applicable).